
    
      Hypothesis: In kidney transplant recipients with active endocapillary proliferation pathology
      of recurrent IgAN, an intravenous infusion of 375mg/m2 of rituximab on 4 consecutive monthly
      dose is superior to conventional therapy in reducing 24-hour proteinuria, and slowing
      progression of recurrent IgAN.
    
  